Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

NCT03694236 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT03694236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03694236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
Lead sponsor
Yonsei University
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 12, 2019
Completion date
May 31, 2027
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

potentially resectable stage ii/iiia nsclc